Sofinnova Biovelocita II has exceeded its target, successfully raising €165 million, with substantial backing from global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. The milestone marks a significant expansion of Sofinnova Partners’ biotech acceleration strategy, extending beyond Italy to include France, the UK, and Denmark, with ambitions to further reach additional European […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!